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The incidence of ischaemic heart disease (IHD) is 
on the rise in Africa. Recent projections suggest that 
by 2030 IHD will become a leading cause of death 
on the continent, surpassing HIV/AIDS.[1] In the 
South African National Burden of Disease Study 
in 2000,[2] IHD was found to be the largest single cause of death in 
the Western Cape Province (12%), followed by stroke (8.8%) and 
HIV/AIDS (8.4%), and non-communicable diseases accounted for 
a larger prop ortion of deaths in the Western Cape (58%) than in the 
rest of South Africa (SA) (38%). In a subsequent study,[3] mortality 
from IHD in Cape Town was found to be very similar to HIV/
AIDS (76 v. 83 deaths/100 000 population, respectively), and IHD 
featured as the leading cause of death from non-communicable 
diseases. The Second National Burden of Disease Study is nearing 
completion and will give us more current data on mortality trends. 
The epidemiological transition of cardiovascular disease described 
by Yusuf et al.[4] suggests that with progression from under-
development to industrialisation we can expect an increasing burden 
of degenerative disease, particularly IHD and stroke.
The use of evidence-based optimal medical therapy (dual antiplatelet 
therapy, statins, beta-blockers and angiotensin-converting enzyme 
inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)) after 
acute coronary syndrome (ACS) is known to reduce 6-month mortality 
by up to 87%.[5] Patients who continue to smoke after an ACS have a 
significantly increased risk of a future acute myocardial infarction (MI) 
compared with those who quit.[6] Furthermore, smoking in the presence 
of established IHD is associated with a significantly increased risk of 
death, including sudden cardiac death. Over an 8-year period, smoking 
cessation reduces this risk to levels comparable to that for people who 
have never smoked.[7] Despite this, medication adherence and smoking 
cessation in patients after discharge are often disappointing.[6-9] Results 
from the Prospective Urban Rural Epidemiology (PURE) study[10] 
suggest that in SA, and in countries with similar income profiles, use 
of these medicines in patients with coronary heart disease at a median 
follow-up period of 4 years varies between 21.1% and 31%, compared 
with 46.5% and 70.9% for upper-income countries. These figures are 
even lower when Africa as a whole is compared with other areas.[10] 
The reasons for discontinuation of medication are diverse, and include 
the high cost of obtaining medicine, high pill burden and lower level 
of education.[11]
To date there are no published SA data on the medium- to long-
term (>6 months) use of secondary prevention medication and 
smoking cessation among patients discharged from hospital after an 
ACS. We designed this cross-sectional study to assess the continued 
use of four selected drug classes and rates of smoking cessation at a 
follow-up period of 6 - 9 months post discharge after an ACS.
Methods
Study design
Cross-sectional analysis with retrospective subject identification.
Self-reported use of evidence-based medicine 
and smoking cessation 6 - 9 months after acute 
coronary syndrome: A single-centre perspective
B Griffiths,1 MB ChB; M Lesosky,1 PhD; M Ntsekhe,2 MD, PhD
1 Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa
2  Division of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital,  
Cape Town, South Africa
Corresponding author: B Griffiths (bpgriffiths@gmail.com)
Background. Good evidence exists to support the use of secondary prevention medications (aspirin, statins, beta-blockers and angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs)) and smoking cessation in patients after acute coronary 
syndromes (ACSs). Little is currently known about adherence to medication and smoking behaviour after discharge in South Africa.
Methods. We conducted a cross-sectional analysis of all patients with a diagnosis of ACS discharged from the Coronary Care Unit at Groote 
Schuur Hospital, Cape Town, between 15 November 2011 and 15 April 2012. Patients were telephoned 6 - 9 months after discharge and 
completed a standardised questionnaire detailing current medication use, reasons for non-adherence and smoking status.
Results. Prescribing of secondary prevention medications at discharge was high (aspirin 94.5%, statins 95.7%, beta-blockers 85.4%, ACEIs/
ARBs 85.9%), and 70.7% of patients were discharged on a combination of all four drugs. At 6 - 9-month follow-up, the pro portion using these 
medications had dropped by 8.9% for aspirin, 10.1% for statins, 6.2% for beta-blockers and 17.9% for ACEIs/ARBs. Only 47.2% remained 
on all four drugs, a reduction of 23.5%. Of the 56.0% of patients who were smokers, 31.4% had stopped smoking.
Conclusions. A significant decline in adherence to recommended therapy 6 - 9 months after discharge and a poor rate of smoking cessation 
suggest that efforts to educate patients about the importance of long-term adherence need to be improved. Furthermore, more effective 
interventions than in-hospital reminders about the hazards of smoking are needed to improve smoking cessation.
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Study population
Groote Schuur Hospital is an 893-bed state-funded tertiary hospital 
in Cape Town, SA. It has a six-bed coronary care unit (CCU) and a 
cardiac catheterisation laboratory. Patients who are admitted to the 
CCU either present directly to the emergency unit or are referred 
from secondary-level institutions. Those who survive their acute 
cardiac insult are discharged home on optimal medical therapy 
and advised about smoking cessation. Clopidogrel, the only P2Y12 
receptor antagonist available in our setting and now widely available, 
was only offered to those patients who underwent percutaneous 
coronary intervention during the study period, owing to funder-
induced prescribing limitations at the time. Apart from a limited 
discussion about the hazards of smoking and its adverse effects on 
coronary artery disease, no specific smoking cessation guidance is 
offered. Long-term care and follow-up take place at the community 
health centre closest to the patient’s home. Medication is supplied free 
of charge to patients who are pensioners, unemployed, or earn less 
than R36 000 per annum, which includes the vast majority of patients 
admitted to our unit.
We retrospectively enrolled all patients discharged alive from 
the CCU with a final diagnosis of unstable angina pectoris, non-ST 
elevation MI or ST-elevation MI during the 5-month period between 
15 November 2011 and 15 April 2012. In each case the consultant 
cardiologist in charge of the patient’s care made the diagnosis.
Approval to conduct the study was obtained from the Human 
Research Ethics Committee, Faculty of Health Sciences, University 
of Cape Town.
Data collection
A medical record review was performed and a standardised data 
capture form completed for each eligible patient. Information 
gathered included demographic characteristics, income group, 
comorbid conditions, medication use on admission, smoking status, 
ACS diagnosis, ACS in-hospital treatment, length of stay and 
discharge medication.
The principal author performed follow-up via a telephone call 
with the patient or primary caregiver at a time period between 6 and 
9 months after discharge. A Xhosa-speaking interpreter performed 
three of the interviews under the guidance of the principal author, 
and a single patient was contacted by email. Verbal informed consent 
for enrolment into the study was obtained at this time from the 
patient or caregiver, and it was made clear that the telephone call was 
for study purposes only.
Patients were encouraged to fetch their current medications and 
actively list them over the telephone. Where a medication of interest 
was not listed, the patient was asked why this was the case. They were 
then asked a standardised smoking question: ‘Do you smoke every 
day, only some days, or never?’ Any reported smoking classified the 
patient as an ongoing smoker.
Interviews were conducted primarily in English, Afrikaans or 
Xhosa only being used if the patient was unable to communicate in 
English or requested otherwise, and the interviewer did not identify 
himself as a doctor unless specifically asked. Where behaviour 
hazardous to health was identified during the interview, such 
as ongoing smoking or non-adherence to medication, this was 
addressed prior to completing the interview.
Statistical analysis
Means and standard deviations were calculated for the full data and 
various data subsets. Comparisons of differences between groups 
were calculated using Fisher’s exact test or the Wilcoxon rank-sum 
test (for categorical and continuous variables), as appropriate. A 
significance level of p<0.05 was used. All statistical analysis was done 
using R 3.0.
Results
Patient characteristics
A total of 164 patients with a diagnosis of ACS were discharged alive 
from the CCU and were therefore eligible for enrolment into the 
study. Their mean age was 58.6 years, and 97 (59.1%) were male. The 
baseline demographic variables, type of ACS and inpatient treatment 
strategy are summarised in Table 1.
Of the 164 patients enrolled in the study, 125 (76.2%) completed 
follow-up interviews. Two patients (1.6%) fell outside the planned 
follow-up range of 6 - 9 months (9.5 and 10.75 months), but were 
included for the sake of completeness and the low likelihood of two 
individuals making a difference to the results. Of the remaining 
patients, 19 (11.6%) had died, 19 (11.6%) were not contactable, and 
one (0.6%) declined participation (Fig. 1). The patients who died 
or were lost to follow-up were more likely to have received medical 
treatment only (p=0.01) and were significantly older (p<0.0001).
Medication use at discharge and at 6 - 9 months’  
follow-up
Of the 164 patients enrolled in the study, 155 (94.5%) were discharged 
on aspirin. Of the patients followed up (n=125), 85.6% (n=107) 
remained on this medication, a reduction of 8.9% (p=0.01). Factors 
associated with ongoing aspirin use, by univariate analysis, were a 
previous diagnosis of IHD (p=0.01) and having undergone coronary 
angiography (p=0.0002). Reasons given for aspirin non-adherence 
were dyspepsia, iron deficiency anaemia, introduction of warfarin 
therapy, and not realising the importance of continued use.
Statins were prescribed to 157 patients (95.7%) at discharge. At 
follow-up 85.6% (107/125) remained on this medication, a reduction 
of 10.1% (p=0.0008). The only factor associated with continued use 
was a diagnosis of hypercholesterolaemia (p=0.02). Reasons given 
for discontinuation of statins were nausea, and not realising the 
importance of continued use.
Beta-blockers were prescribed for 140 patients (85.4%) at 
discharge. At follow-up 79.2% (99/125) remained on this medication, 
a reduction of 6.2% (p<0.0001). Factors associated with adherence 
were hypercholesterolaemia (p=0.005), a previous diagnosis of 
IHD (p=0.005), and female gender (p=0.02). Reasons given for 
discontinuation were doctor-initiated cessation due to a reduced 
heart rate, and not realising the importance of continued use.
ACEIs/ARBs were prescribed for 141 patients (85.9%) at discharge. 
At follow-up, 68.0% (85/125) were still using this medication, the 
largest reduction in use for any of the four drug classes at 17.9% 
(p<0.0001). Ongoing use was associated with a previous diagnosis 
of IHD (p=0.04). Reasons given for discontinuation were angio-
oedema, cough, doctor-initiated cessation due to low blood pressure, 
and not realising the importance of continued use.
The number of patients discharged on a combination of all four 
drug classes was 116 (70.7%). Of the 125 patients followed up, only 
47.2% (n=59) remained on all four drugs, a reduction of 23.5% 
(p=0.001). A total of five patients (4.0%) had stopped all medications 
because they did not realise the importance of ongoing use. Results 
are summarised in Table 2.
Smoking on admission and at 6 - 9 months’ follow-up
Of the 125 patients who were followed up, 70 (56.0%) had been 
active smokers on admission to hospital, and 22 of these had 
had stopped smoking by the time of the interview, representing 
a smoking cessation rate of 31.4%. One patient had taken up 
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smoking for the first time after discharge. 
The only factor independently associated 
with an increased rate of smoking cessation, 
by univariate analysis, was a longer length 
of hospital stay (p=0.006). We could find no 
relationship between smoking cessation rate 
and age, gender, income category, comorbid 
conditions, admission diagnosis or treatment 
received.
Discussion
There was good early initiation of secondary 
prevention medication after ACS in our 
cohort of patients. It has been shown that 
patients who do not start medication shortly 
after the acute event are unlikely to ever 
have medication added, and a focused effort 
to start treatment in the immediate post-
infarction period is likely to provide long-
term benefit.[12] When we compare these 
findings with those of the Clinical Pathways 
for Acute Coronary Syndromes in China 
(CPACS)[8] and the Global Registry of Acute 
Coronary Events (GRACE)[9] studies, our 
prescribing rates for the four selected drugs 
at discharge after ACS are higher for all 
drug classes (Table 3 and Fig. 2). Since both 
the above studies used the same method 
of follow-up as we did, namely telephone 
calls and active listing of medications, they 
provide a reasonable comparison. The 
CPACS investigators felt that there was a 
significant gap between evidence and practice 
in medication prescribing after ACS, which 
was not found in our study. It should be noted 
that the low rates of prescribing of secondary 
prevention medication found in the GRACE 
study may in part be because the data were 
collected from 1999 to 2003, when less 
emphasis was placed on these medications. 
Our finding of a high early initiation rate of 
all four recommended drugs is important and 
demonstrates that adherence to best-practice 
guidelines in our setting is feasible.
Table 1. Demographic characteristics of patients enrolled, completing interviews and lost to follow-up
Variable
Enrolled
(N=164)
Completed interview 
(N=125)
Lost to follow-up
(N=39)
Age (yrs), mean (SD) 58.6 (11.2) 57.0 (10.9) 63.8 (11.0)
Male, n (%) 97 (59.1) 71 (56.8) 26 (66.7)
Income category, n (%)
Unemployed/pensioner 47 (28.6) 31 (24.8) 16 (41.0)
Income <R36 000 p.a. 85 (51.8) 66 (52.8) 19 (48.7)
Income <R72 000 p.a. 14 (8.5) 14 (11.2) -
Income >R72 000 p.a. 13 (7.9) 9 (7.2) 4 (10.3)
Private medical aid/foreigner 4 (2.4) 4 (3.2) -
Unknown 1 (0.6) 1 (0.8) -
Medical history, n (%)
Hypertension 99 (60.3) 71 (56.8) 28 (71.8)
Diabetes mellitus 51 (31.0) 36 (28.8) 15 (38.5)
Hypercholesterolaemia 73 (44.5) 57 (45.6) 16 (41.0)
IHD 83 (50.6) 61 (48.8) 22 (56.4)
Current smoker, n (%) 90 (54.8) 70 (56.0) 20 (51.3)
Diagnosis, n (%)
ST-elevation MI 59 (35.9) 44 (35.2) 15 (38.5)
Non ST-elevation MI 77 (46.9) 57 (45.6) 20 (51.3)
Unstable angina pectoris 28 (17.0) 24 (19.2) 4 (10.3)
Treatment, n (%)
Medical only 95 (57.9) 65 (52.0) 30 (76.9)
PCI 59 (35.9) 50 (40.0) 9 (23.1)
Coronary artery bypass graft 10 (6.09) 10 (8.0) -
Angiogram (including PCI), n (%) 112 (68.2) 92 (73.6) 20 (51.3)
Length of stay (days), mean (SD) 3.018 (1.9) 2.98 (2.0) 3.13 (1.7)
SD = standard deviation; p.a. = per annum; IHD = ischaemic heart disease (previous myocardial infarction or unstable angina pectoris); MI = myocardial infarction;  
PCI = percutaneous coronary intervention.
Discharged alive
with a diagnosis of
ACS (N=164)
Not 
contactable
(n=19)
Declined
participation
(n=1)
Died
(n=19)
Completed
interviews
(n=125)
Fig. 1. Flow diagram demonstrating follow-
up of enrolled patients. (ACS = acute coronary 
syndrome.)
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We found a significant increase in the rate of 
non-adherence to the selected medications 
in our group of patients beyond 6 months. 
Medication cessation for appropriate reasons, 
such as ACEI-induced angio-oedema or beta-
blocker-induced symptomatic bradycardia, 
is unavoidable and expected for a minority 
of patients. What is more concerning is that 
patients stopped medication because they 
did not realise the importance of ongoing 
use, which was found to be a reason for non-
adherence for each of the four drug classes, 
and for the five patients who stopped all four 
drugs completely. Rates of discontinuation of 
medication were higher for most of the drug 
classes when compared with the CPACS and 
GRACE studies (Table 3 and Fig. 2), the 
exceptions being lipid-lowering agents when 
compared with CPACS (a 10.1% drop-off in 
adherence v. 14.6%) and beta-blockers when 
compared with GRACE (6.2% v. 6.9%). It 
is not clear from our data why the rates 
of non-adherence are higher. There is no 
clear link to a language barrier, as all but 
three of the patients could speak English or 
Afrikaans, both of which are spoken in the 
CCU by doctors and nursing staff. There was 
also no demonstrable link between income 
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Fig. 2. Graphic representation of the comparison between medication use at discharge and follow-up 
in the present study and two similar studies. (ACEI = angiotensin-converting enzyme inhibitor; BB = 
beta-blocker; LLA = lipid-lowering agent.)
Table 2. Medication use at discharge and follow-up
Discharge (N=164), n (%) Follow-up (N=125), n (%) Reduction in use (%) p-value
Aspirin 155 (94.5) 107 (85.6) 8.9 0.01
Statin 157 (95.7) 107 (85.6) 10.1 0.0008
Beta-blocker 140 (85.4) 99 (79.2) 6.2 <0.0001
ACEI/ARB 141 (85.9) 85 (68.0) 17.9 <0.0001
Four-drug comb. 116 (70.7) 59 (47.2) 23.5 0.001
ACEI/ARB = angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
Table 3. Comparison between medication use at discharge and follow-up in the present study and two similar studies
Griffiths et al. (SA, present study) Bi et al.[8] (CPACS China) Eagle et al.[9] (GRACE multi-country)
DC 
(N=164) 
n (%)
FU 
(N=125) 
n (%) Diff., %
DC 
(N=2 901) 
n (%) 
FU 
(N=2 521) 
n (%) Diff., %
DC 
(N=13 830) 
n (%) 
FU 
(N=13 830)
n (%) Diff., %
Aspirin 155 
(94.5)
107 (85.6) -8.9 2 687 
(92.7)
2 211  
(88.2)
-4.5 12 463 
(90.1)
11 465 
(82.9)
-7.2
Lipid-lowering 
agent
157 
(95.7)
107 (85.6) -10.1 2 332 
(80.4)
1 654  
(65.8)
-14.6 6 320 
(45.7)
5 522  
(39.9)
-6.1
Beta-blocker 140 
(85.4)
99  
(79.2)
-6.2 2 031 
(70.0)
1 798  
(71.8)
+1.8 7 738 
(56.0)
6 796  
(49.1) 
-6.9
ACEI/ARB 141 
(85.9)
85  
(68.0)
-17.9 2 194 
(75.6)
1 694  
(67.2)
-8.4 2 379 
(17.2)
1 906  
(13.8)
-3.4
Four-drug comb. 116 
(70.7)
59  
(47.2)
-23.5 1 384 
(47.7)
1 088  
(43.6)
-4.1 NA NA NA
SA = South Africa; DC = medication prescribed at discharge; FU = medication use reported at follow-up; Diff. = difference between DC and FU;  
ACEI/ARB = angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; CPACS = Clinical Pathways for Acute Coronary Syndromes in China study;  
GRACE = Global Registry of Acute Coronary Events study; NA = not applicable. 
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category and adherence, and SA and China are both rated as upper 
middle-income countries by the World Bank Country Classification, 
so adherence rates based purely on income would be expected 
to be similar. It is possible that level of education and insight 
into disease could play a role, but these were not included in our 
questionnaire. No patient mentioned a shortage of medication at a 
local clinic as a reason for discontinuation. The frequent reporting 
of non-adherence to medication as a result of not understanding 
the importance of ongoing use implies that good communication 
with the patient during the index hospital admission, with a focus 
on education about the disease and future treatment, is essential. 
Enhanced communication between treating doctor and patient, 
as well as involving ancillary healthcare providers such as nursing 
staff and pharmacists, have both been shown to improve adherence, 
both during admission and through community-based cardiac 
rehabilitation programmes. Innovative measures such as the use of 
short message service (SMS) reminder technology for mobile phones, 
which has been demonstrated to improve adherence to antiretroviral 
medication in SA and to other chronic medications elsewhere, should 
be looked at to improve adherence in our setting.
More of our patients continued to smoke after an ACS than has 
been found in similar studies. Evidence from the PURE study shows 
a clear link between smoking cessation after a coronary heart disease 
or stroke event and country income category, with cessation rates 
highest in upper-income countries, and decreasing with declining 
income category of the country.[13] The smoking cessation rate in 
upper middle-income countries such as SA was found to be 54.6%,[13] 
which is still higher than the 31% rate in our group. We did not ask 
patients whether they had tried to stop smoking, or indeed whether 
they wanted to try to stop, so the rate of failed attempts at smoking 
cessation is unknown. The Western Cape is known to have the highest 
smoking rate of all the SA provinces, at 44.7% of men and 27% of 
women.[14] A recent Cochrane review found that intensive behavioural 
interventions in hospitalised patients, followed by at least a month of 
outpatient supportive contact, was effective at significantly improving 
smoking cessation rates, and it should be considered as an option in 
this group of patients. The addition of nicotine replacement therapy 
in gum or patch form further improves smoking cessation. At present 
there is not sufficient evidence to prove that bupropion or varenicline 
in addition to intensive counselling in hospitalised patients increases 
cessation rates over intensive counselling alone.[15] The smoking 
cessation rates in our cohort suggest that adoption of these and other 
evidence-based methods of influencing smoking behaviour should be 
made an urgent priority.
Study limitations
Our study has a number of limitations. We measured adherence 
by self-report, with no electronic or pill count data to back up our 
findings. Although this method of active listing of medications over 
the telephone tends to overestimate adherence, it has been used 
successfully in similar studies[8,9,11] and is highly specific. While 
measurement of smoking by self-report can lead to an overestimation 
of smoking cessation, this method has been shown to correlate well 
with cotinine testing in most studies. Other limitations include 
enrolling patients from only a single urban tertiary centre, having a 
relatively small sample size, and borderline significance of univariate 
analyses. Not knowing the medication adherence and smoking 
cessation rates of those patients who died is another limitation, as 
this information may have improved insight into mortality in this 
group of patients. These factors raise the concern that our findings 
may not be representative of the population as a whole. In order to 
avoid selection bias at enrolment, we included every patient with ACS 
discharged alive from the CCU over the selected 5-month period, 
and did not limit inclusion to those patients who were followed up 
at our institution. SA is a diverse country with broad variations in 
culture, income and access to healthcare, and a similar multicentre, 
prospective study in future could improve our understanding of the 
challenges posed by medication adherence and smoking cessation 
after ACS.
Conclusion
This study has provided valuable insight into prescribing practices, 
medium-term adherence patterns after ACS, and smoking cessation 
rates beyond 6 months, areas for which there are currently no published 
data in our setting. Three findings were of particular importance: (i) 
we found that our prescribing of secondary prevention medication 
at discharge is high (70.7% for the four-drug combination); (ii) we 
noted that a fairly large proportion of our patients are discontinuing 
medication within a 6 - 9-month period (23.5% for the four-drug 
combination); and (iii) we demonstrated that a large proportion 
(68.6%) of patients who were active smokers on admission to hospital 
continued to smoke, giving a cessation rate of 31.4%. Given the 
importance of smoking cessation in improving short- and long-term 
outcomes, more focused strategies to improve this adverse behaviour, 
particularly in this high risk population, are required.
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